LAC Med Berhad (5341) Fair Value & Analysis
Healthcare · MY · Market cap 284M MYR
Fair value as of: Jul 18, 2026
From 17 valuation models · updated 23 days ago
Share price +20.9% over the past month.
Below-average quality, screening 25% undervalued on our models.
What matters now
- Solid quality (47/100) at a price below fair value, the discount is the argument here, not the business quality.
- Our model range runs from 0.7900 MYR (bear) to 1.32 MYR (bull), base 1.05 MYR. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 47/100 (below-average quality) with high evidence: the data supports the verdict.
Price vs Fair Value (8 months)
White line = price, green steps = our fair value per fiscal year. As of Jul 18, 2026.
How to read this chart
8‑month range 0.6500 MYR – 1.24 MYR · fair‑value band 0.7900 MYR – 1.32 MYR · the 0.8400 MYR price screens below the 1.05 MYR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Jul 18, 2026.
Analysis
LAC Med Berhad (5341) currently trades at 0.8400 MYR, while our model-based Fair Value estimate is 1.05 MYR, implying the stock looks roughly 25.0% undervalued today. The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, LAC Med Berhad generated revenue of 184M MYR at a net margin of 9.8%. Revenue declined 38.1% year over year. It earns a return on equity of 20.8%. Net debt stands at 4.4M MYR. Fundamentals as of Jul 18, 2026
Our scenario range runs from 0.7900 MYR (bear case) to 1.32 MYR (bull case); at 0.8400 MYR, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 37% below its 52-week high and 21% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at 25%, 5341 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 17 models by family
Widest divergence: Growth Earnings (1.26 MYR) versus Dividend Discount (0.1400 MYR). Highest evidence: Residual Income (76).
Notify me when 5341 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 18, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 50 · Market factors (momentum, volatility) 26
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
LAC Med Berhad engages in the distribution, supply, and integration of medical devices, diagnostic equipment, and digital health solutions for diagnostic purposes in Malaysia and Indonesia. The company offers diagnostic equipment, radiographic, ultrasound, magnetic resonance imaging (MRI), as well as software systems and maintenance services.
Full company description
LAC Med Berhad engages in the distribution, supply, and integration of medical devices, diagnostic equipment, and digital health solutions for diagnostic purposes in Malaysia and Indonesia. The company offers diagnostic equipment, radiographic, ultrasound, magnetic resonance imaging (MRI), as well as software systems and maintenance services. It serves hospitals, clinics, and healthcare providers. The company was incorporated in 2003 and is headquartered in Petaling Jaya, Malaysia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2025 · reported fiscal years
LAC Med Berhad reported revenue of 202M MYR in FY2025 versus 107M MYR in FY2022, a compound +23.7%/yr. Reported net income was 21.9M MYR in FY2025, compounding +18.9%/yr from FY2022.
Watch 5341: get an alert when its fair value changes →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 30/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 18, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare LAC Med Berhad with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is LAC Med Berhad (5341) overvalued or undervalued?
What is the fair value of 5341?
What is the quality score of 5341?
What is the revenue of LAC Med Berhad (5341)?
What is the net profit margin of 5341?
Does LAC Med Berhad pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track LAC Med Berhad and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.